Intravenous Administration of Zoledronate in Children with Bone-Associated Langerhans Cell Histiocytosis
-
By
-
Sy, Jann Adriel
-
Quah, Thuan Chong
-
Tee, Pian Pian
-
Ho, Cindy Wei Li
-
April 15, 2026
-
Clinical Scorecard: Intravenous Administration of Zoledronate in Children with Bone-Associated Langerhans Cell Histiocytosis
At a Glance
| Category | Detail |
|---|
| Condition | Langerhans Cell Histiocytosis (LCH) with bone involvement |
| Key Mechanisms | Adjunctive therapy for pain relief and skeletal stability |
| Target Population | Children with osseous LCH |
| Care Setting | Pediatric hematology-oncology referral center |
Key Highlights
- 100% of symptomatic patients experienced pain improvement
- Median time to pain improvement was 18 days post-infusion
- Radiographic outcomes showed complete resolution in 2 patients and improvement in 6
- Zoledronate was well tolerated with transient fever in 4 patients
- No significant adverse effects such as hypocalcemia or osteonecrosis of the jaw were observed
Guideline-Based Recommendations
Diagnosis
- Evaluate bone involvement in pediatric LCH through clinical and radiologic assessment
Management
- Consider intravenous zoledronate for painful active bone lesions and progressive relapsed disease
Monitoring & Follow-up
- Monitor for pain response and radiologic outcomes post-zoledronate administration
Risks
- Transient fever; no significant hypocalcemia or osteonecrosis of the jaw reported
Patient & Prescribing Data
Children with varying presentations of osseous LCH
Zoledronate used as a chemotherapy-sparing approach in selected patients
Clinical Best Practices
- Administer zoledronate for pain relief in weight-bearing bone lesions
- Consider concurrent oral chemotherapy for systemic disease management
- Evaluate prior treatment history to tailor zoledronate use
References
